YGEN.L Regulatory News (YGEN)

Yourgene Health plc

("Yourgene" or the "Company")

Yourgene's Ranger® Technology to be presented at Labroots webinar

Manchester, UK - 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger® Technology, which was acquired with Coastal Genomics Inc in August 2020, will be presented by Yourgene's strategic customer, Labcorp, at the Labroots 2021 Clinical Diagnostics and Research Virtual Symposium Event, taking place on Wednesday 10 November 2021.

During the presentation titled, 'Size selection of cell-free DNA enhances signal for the detection of tumor-specific variants in cancer patients', Kimberly Holden, Research Associate III at Labcorp, will demonstrate how Yourgene's Ranger® Technology is used with the NIMBUS Select platform to overcome historic challenges in circulating tumour DNA (ctDNA) variant detection. The NIMBUS Select is a proprietary instrument combining Yourgene's Ranger® Technology in partnership with the Microlab NIMBUS platform from Hamilton Company, a leading global instrument manufacturer.

Labroots Clinical Diagnostics and Research Virtual Event brings together clinicians, researchers, medical experts and professionals and aims to elevate the level of collaboration and in turn, advance clinical diagnostics, research and medicine. The Labroots event will include presentations on: Emerging Diagnostic Technologies, COVID-19 Screening and Diagnosis, Medical Imaging and The Labs Role in Advancing Equity. Yourgene will also be sponsoring a virtual booth at the event.

Investors can register to dial into the Labroots Webinar here: https://www.labroots.com/virtual-event/clinical-diagnostics-research-2021

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.